-transparent.png){kind=logo}
Sepimostat mesilate (FUT-187: 6-amidino-2-naphthyl 4-[(4,5-dihydro-1H-imidazol-2-yl) amino] benzoate dimethane sulfonate) is a newly synthesized serine protease inhibitor. In the present study, the oral administration of FUT-187 inhibited stasis-induced venous thrombosis in rats. We supposed that such effect of this compound was caused by its inhibitory effect on coagulation. However, the dose of FUT-187 that was effective at inhibiting thrombosis (10 and 30 mg/kg, po) had no effect on the plasma recalcification time (PRCT), activated partial thromboplastin time (APTT) and prothrombin time (PT) in rats. Therefore, we investigated the fibrinolytic activity of FUT-187 in rat plasma. The results revealed that rat plasma after FUT-187 administration exhibited increased amidolytic activity for a plasmin-, tissue-type plasminogen activator (t-PA)-, urokinase-type plasminogen activator (u-PA)-, factor Xa-, factor XIa- and factor XIIa-sensitive synthetic peptide substrate. On the other hand, the inhibitory effect of FUT-187 in the thrombosis model was not affected by additional treatment with epsilon-amino-n-caproic acid (EACA), a plasmin-mediated fibrinolysis inhibitor. These results suggest that even if FUT-187 enhanced fibrinolysis, it would be independent of a plasmin-mediated fibrinolytic pathway. To characterize the fibrinolytic activity, which might reduce the thrombus weight in the thrombosis model administered FUT-187, we carried out fibrinogen zymography, and clarified that FUT-187 enhanced the formation of a 20-kDa fibrinolytic fragment. Interestingly, this fragment was not affected by t-PA. Consequently, we consider that the inhibitory effect of FUT-187 on venous thrombosis model is caused by fibrinolysis, which is attributable to the 20-kDa fragment, rather than by inhibition of thrombus formation.
A Tsuruda, and
S Kanno, and
H Ohtani, and
R Suzuki, and
M Nishioka, and
Y Koshiyama, and
M Kurumi
October 1995,
Arzneimittel-Forschung,
A Tsuruda, and
S Kanno, and
H Ohtani, and
R Suzuki, and
M Nishioka, and
Y Koshiyama, and
M Kurumi
July 1999,
The Journal of pharmacy and pharmacology,
A Tsuruda, and
S Kanno, and
H Ohtani, and
R Suzuki, and
M Nishioka, and
Y Koshiyama, and
M Kurumi
October 1964,
Thrombosis et diathesis haemorrhagica,
A Tsuruda, and
S Kanno, and
H Ohtani, and
R Suzuki, and
M Nishioka, and
Y Koshiyama, and
M Kurumi
May 1995,
Gan to kagaku ryoho. Cancer & chemotherapy,
A Tsuruda, and
S Kanno, and
H Ohtani, and
R Suzuki, and
M Nishioka, and
Y Koshiyama, and
M Kurumi
December 1974,
Thrombosis et diathesis haemorrhagica,
A Tsuruda, and
S Kanno, and
H Ohtani, and
R Suzuki, and
M Nishioka, and
Y Koshiyama, and
M Kurumi
January 1980,
Thrombosis research,
A Tsuruda, and
S Kanno, and
H Ohtani, and
R Suzuki, and
M Nishioka, and
Y Koshiyama, and
M Kurumi
November 2021,
Bulletin of experimental biology and medicine,
A Tsuruda, and
S Kanno, and
H Ohtani, and
R Suzuki, and
M Nishioka, and
Y Koshiyama, and
M Kurumi
January 1972,
Acta Universitatis Carolinae. Medica. Monographia,
A Tsuruda, and
S Kanno, and
H Ohtani, and
R Suzuki, and
M Nishioka, and
Y Koshiyama, and
M Kurumi
March 1989,
The Journal of pharmacology and experimental therapeutics,
A Tsuruda, and
S Kanno, and
H Ohtani, and
R Suzuki, and
M Nishioka, and
Y Koshiyama, and
M Kurumi
March 1995,
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
